Beranda › Kanker Kandung Kemih › California › Baldwin Park
Uji klinis Kanker Kandung Kemih di Baldwin Park, CA
14 studi untuk Kanker Kandung Kemih mencari peserta di lokasi sekitar Baldwin Park (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Menerima pesertaFase 1
- City of Hope National Medical Center, Duarte · 4 mi jauhnya
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Menerima pesertaFase 2
- City of Hope - Duarte Cancer Center, Duarte · 4 mi jauhnya
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- City of Hope, Duarte · 4 mi jauhnya
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Menerima pesertaFase 1
- City of Hope National Medical Center, Duarte · 4 mi jauhnya
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Menerima pesertaFase 2
- City of Hope Comprehensive Cancer Center, Duarte · 4 mi jauhnya
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Menerima pesertaFase 1/2
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte · 4 mi jauhnya
- City of Hope Investigational Drug Services (IDS), Duarte · 4 mi jauhnya
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Menerima pesertaFase 1
- City of Hope Cancer Center-Duarte, Duarte · 4 mi jauhnya
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Menerima pesertaFase 1
- City of Hope, Duarte · 4 mi jauhnya
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Menerima pesertaFase 1
- City of Hope, Duarte · 4 mi jauhnya
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Menerima pesertaFase 2
- Kaiser Permanente Baldwin Park Medical Center, Baldwin Park
Telehealth Intervention for Ostomy Self-Management
Menerima pesertaFase 2
- City of hope Medical Center, Duarte · 4 mi jauhnya
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- City of Hope, Duarte · 4 mi jauhnya
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Menerima peserta
- City of Hope Medical Center, Duarte · 4 mi jauhnya
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Duarte · 4 mi jauhnya
Uji klinis Kanker Kandung Kemih di kota lain
- New York City, NY35 studi
- Nashville, TN31 studi
- Houston, TX31 studi
- Dallas, TX27 studi
- Boston, MA26 studi
- Washington, DC26 studi
- Los Angeles, CA24 studi
- Baltimore, MD24 studi
- St. Louis, MO22 studi
- Philadelphia, PA21 studi
- Seattle, WA21 studi
- Edison, NJ21 studi
Studi lain di Baldwin Park
- Kanker Payudara45 studi
- Leukemia Mieloid Akut40 studi
- Kanker Kolorektal38 studi
- Kanker Paru Non-Sel Kecil36 studi
- Kanker (semua jenis)33 studi
- Kanker Prostat30 studi
- Kanker Metastatik30 studi
- Sindrom Mielodisplastik26 studi
- Kanker Ovarium25 studi
- Kanker Paru24 studi
- Mieloma Multipel23 studi
- Kanker Lambung22 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.